Imunon, Inc. (IMNN) stock
IMNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.61+0.02 (+3.06%)
Close on Nov 17, 2026Market cap $3.44MP/E –Yield –
Imunon r&d expenses
Research and development expenses are spending on new products and technology.
Imunon's R&D Expenses for the twelve months ending Mar 31, 2026 was $7.95M, down 24.3% year over year. For fiscal 2025 it was $7.78M, down 33.2% from the year before. Over ten years it grew -6.1% a year on average. The highest annual figure on record is $19.86M in fiscal 2011.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.78M | -33.2% |
| FY2024 | Dec 31, 2024 | $11.64M | +3.1% |
| FY2023 | Dec 31, 2023 | $11.29M | -3.8% |
| FY2022 | Dec 31, 2022 | $11.73M | +10.5% |
| FY2021 | Dec 31, 2021 | $10.62M | -6.4% |
| FY2020 | Dec 31, 2020 | $11.34M | -13.2% |
| FY2019 | Dec 31, 2019 | $13.07M | +10.1% |
| FY2018 | Dec 31, 2018 | $11.87M | -9.3% |
| FY2017 | Dec 31, 2017 | $13.08M | -10.6% |
| FY2016 | Dec 31, 2016 | $14.62M | -0.3% |
| FY2015 | Dec 31, 2015 | $14.66M | -2.1% |
| FY2014 | Dec 31, 2014 | $14.97M | +59.9% |
| FY2013 | Dec 31, 2013 | $9.36M | -40.6% |
| FY2012 | Dec 31, 2012 | $15.77M | -20.6% |
| FY2011 | Dec 31, 2011 | $19.86M | +35.0% |
| FY2010 | Dec 31, 2010 | $14.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $2.34M | +8.0% |
| Q4 FY2025 | Dec 31, 2025 | $2.49M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.90M | -42.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.23M | -56.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.17M | -34.3% |
| Q4 FY2024 | Dec 31, 2024 | $2.23M | -37.2% |
| Q3 FY2024 | Sep 30, 2024 | $3.29M | +66.3% |
| Q2 FY2024 | Jun 30, 2024 | $2.82M | -6.1% |
| Q1 FY2024 | Mar 31, 2024 | $3.29M | +36.7% |
| Q4 FY2023 | Dec 31, 2023 | $3.55M | +10.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.98M | -36.0% |
| Q4 FY2022 | Dec 31, 2022 | $3.00M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | $2.41M | -2.4% |
| Q2 FY2022 | Jun 30, 2022 | $3.23M | +24.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.10M | +20.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.99M | +6.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.47M | -0.9% |
| Q2 FY2021 | Jun 30, 2021 | $2.59M | -13.3% |
| Q1 FY2021 | Mar 31, 2021 | $2.57M | -15.7% |
| Q4 FY2020 | Dec 31, 2020 | $2.81M | -8.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.49M | -32.2% |
| Q2 FY2020 | Jun 30, 2020 | $2.99M | -15.9% |
| Q1 FY2020 | Mar 31, 2020 | $3.05M | +10.3% |
| Q4 FY2019 | Dec 31, 2019 | $3.07M | +30.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.67M | +68.0% |
| Q2 FY2019 | Jun 30, 2019 | $3.56M | -22.5% |
| Q1 FY2019 | Mar 31, 2019 | $2.77M | +1.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.34M | -26.9% |
| Q3 FY2018 | Sep 30, 2018 | $2.19M | -34.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.59M | +37.2% |
| Q1 FY2018 | Mar 31, 2018 | $2.74M | -21.1% |
| Q4 FY2017 | Dec 31, 2017 | $3.21M | -11.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.35M | -20.7% |
| Q2 FY2017 | Jun 30, 2017 | $3.35M | +0.4% |
| Q1 FY2017 | Mar 31, 2017 | $3.48M | +1.0% |
| Q4 FY2016 | Dec 31, 2016 | $3.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.23M | – |
| Q2 FY2016 | Jun 30, 2016 | $3.34M | – |
| Q1 FY2016 | Mar 31, 2016 | $3.44M | – |
See a number that looks wrong?